

Peds Immunization

Can also download cdc vaccination schedule app via your phone store

Table 1 Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022

These recommendations must be read with the notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars. To determine minimum intervals between doses, see the catch-up schedule (Table 2).

| Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | 18 mos | 19–23 mos | 2–3 yrs | 4–6 yrs | 7–10 yrs | 11–12 yrs | 13–15 yrs | 16 yrs | 17–18 yrs |
|---|----------------------|--------------------------|----------------------|----------------------|--------------------------|--------------------------|--|--------------------------|--------|-----------|---------|----------------------|----------|-----------|----------------------|----------------------|-----------|
| Hepatitis B (HepB) | 1 st dose | ← 2 nd dose → | | | ← 3 rd dose → | | | | | | | | | | | | |
| Rotavirus (RV): RV1 (2-dose series), RV5 (3-dose series) | | | 1 st dose | 2 nd dose | See Notes | | | | | | | | | | | | |
| Diphtheria, tetanus, acellular pertussis (DTaP <7 yrs) | | | 1 st dose | 2 nd dose | 3 rd dose | | | ← 4 th dose → | | | | 5 th dose | | | | | |
| Haemophilus influenzae type b (Hib) | | | 1 st dose | 2 nd dose | See Notes | | ← 3 rd or 4 th dose, See Notes → | | | | | | | | | | |
| Pneumococcal conjugate (PCV13) | | | 1 st dose | 2 nd dose | 3 rd dose | | ← 4 th dose → | | | | | | | | | | |
| Inactivated poliovirus (IPV <18 yrs) | | | 1 st dose | 2 nd dose | | ← 3 rd dose → | | | | | | 4 th dose | | | | | |
| Influenza (IIV4) | | | | | | | | | | | | | | | | | |
| or | | | | | | | | | | | | | | | | | |
| Influenza (LAIV4) | | | | | | | | | | | | | | | | | |
| Measles, mumps, rubella (MMR) | | | | | See Notes | | ← 1 st dose → | | | | | 2 nd dose | | | | | |
| Varicella (VAR) | | | | | | | ← 1 st dose → | | | | | 2 nd dose | | | | | |
| Hepatitis A (HepA) | | | | | See Notes | | | | | | | | | | | | |
| Tetanus, diphtheria, acellular pertussis (Tdap ≥7 yrs) | | | | | | | | | | | | | | | 1 dose | | |
| Human papillomavirus (HPV) | | | | | | | | | | | | | | | See Notes | | |
| Meningococcal (MenACWY-D ≥9 mos, MenACWY-CRM ≥2 mos, MenACWY-TT ≥2 years) | | | | | | | | | | | | | | | 1 st dose | 2 nd dose | |
| Meningococcal B (MenB-4C, MenB-FHbp) | | | | | | | | | | | | | | | | | |
| Pneumococcal polysaccharide (PPSV23) | | | | | | | | | | | | | | | | | |
| Dengue (DEN4CYD; 9–16 yrs) | | | | | | | | | | | | | | | | | |

Range of recommended ages for all children
Range of recommended ages for catch-up vaccination
Range of recommended ages for certain high-risk groups
Recommended vaccination can begin in this age group
Recommended vaccination based on shared clinical decision-making
No recommendation/not applicable

Table 2 Recommended Catch-up Immunization Schedule for Children and Adolescents Who Start Late or Who Are More than 1 Month Behind, United States, 2022

The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child's age. **Always use this table in conjunction with Table 1 and the Notes that follow.**

| Children age 4 months through 6 years | | | | | |
|---|--|---|---|--|------------------|
| Vaccine | Minimum Age for Dose 1 | Minimum Interval Between Doses | | | |
| | | Dose 1 to Dose 2 | Dose 2 to Dose 3 | Dose 3 to Dose 4 | Dose 4 to Dose 5 |
| Hepatitis B | Birth | 4 weeks | 8 weeks and at least 16 weeks after first dose minimum age for the final dose is 24 weeks | | |
| Rotavirus | 6 weeks Maximum age for first dose is 14 weeks, 6 days. | 4 weeks | 4 weeks maximum age for final dose is 8 months, 0 days | | |
| Diphtheria, tetanus, and acellular pertussis | 6 weeks | 4 weeks | 4 weeks | 6 months | 6 months |
| Haemophilus influenzae type b | 6 weeks | No further doses needed if first dose was administered at age 15 months or older. 4 weeks if first dose was administered before the 1 st birthday. 8 weeks (as final dose) if first dose was administered at age 12 through 14 months. | No further doses needed if previous dose was administered at age 15 months or older 4 weeks if current age is younger than 12 months and first dose was administered at younger than age 7 months and at least 1 previous dose was PRP-T (ActHib®, Pentacel®, Hiberix®), Vaxelis® or unknown 8 weeks and age 12 through 59 months (as final dose) if current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR if current age is 12 through 59 months and first dose was administered before the 1 st birthday and second dose was administered at younger than 15 months; OR if both doses were PedvaxiHIB® and were administered before the 1st birthday | 8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before the 1 st birthday. | |
| Pneumococcal conjugate | 6 weeks | No further doses needed for healthy children if first dose was administered at age 24 months or older. 4 weeks if first dose was administered before the 1 st birthday 8 weeks (as final dose for healthy children) if first dose was administered at the 1 st birthday or after | No further doses needed for healthy children if previous dose was administered at age 24 months or older 4 weeks if current age is younger than 12 months and previous dose was administered at <7 months old 8 weeks (as final dose for healthy children) if previous dose was administered between 7–11 months (wait until at least 12 months old); OR if current age is 12 months or older and at least 1 dose was administered before age 12 months | 8 weeks (as final dose) This dose only necessary for children age 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age. | |
| Inactivated poliovirus | 6 weeks | 4 weeks | 4 weeks if current age is <4 years 6 months (as final dose) if current age is 4 years or older | 6 months (minimum age 4 years for final dose) | |
| Measles, mumps, rubella | 12 months | 4 weeks | | | |
| Varicella | 12 months | 3 months | | | |
| Hepatitis A | 12 months | 6 months | | | |
| Meningococcal ACWY | 2 months MenACWY-CRM 9 months MenACWY-D 2 years MenACWY-TT | 8 weeks | See Notes | See Notes | |
| Children and adolescents age 7 through 18 years | | | | | |
| Meningococcal ACWY | Not applicable (N/A) | 8 weeks | | | |
| Tetanus, diphtheria, and acellular pertussis | 7 years | 4 weeks | 4 weeks if first dose of DTaP/DT was administered before the 1 st birthday 6 months (as final dose) if first dose of DTaP/DT or Tdap/Td was administered at or after the 1 st birthday | 6 months if first dose of DTaP/DT was administered before the 1 st birthday | |
| Human papillomavirus | 9 years | Routine dosing intervals are recommended. | | | |
| Hepatitis A | N/A | 6 months | | | |
| Hepatitis B | N/A | 4 weeks | 8 weeks and at least 16 weeks after first dose | | |
| Inactivated poliovirus | N/A | 4 weeks | 6 months A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. | A fourth dose of IPV is indicated if all previous doses were administered at <4 years or if the third dose was administered <6 months after the second dose. | |
| Measles, mumps, rubella | N/A | 4 weeks | | | |
| Varicella | N/A | 3 months if younger than age 13 years. 4 weeks if age 13 years or older | | | |
| Dengue | 9 years | 6 months | 6 months | | |

Table 3

Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2022

Always use this table in conjunction with Table 1 and the Notes that follow.

Always use this table in conjunction with table 1 and the notes that follow.

| VACCINE | INDICATION | | | | | | | | | |
|---|------------|--|--|---|---|---------------------------------------|------------------------------|--|-----------------------|----------|
| | Pregnancy | Immunocompromised status (excluding HIV infection) | HIV infection CD4+ count ¹ | | Kidney failure, end-stage renal disease, or on hemodialysis | Heart disease or chronic lung disease | CSF leak or cochlear implant | Asplenia or persistent complement component deficiencies | Chronic liver disease | Diabetes |
| | | | <15% or total CD4 cell count of <200/mm ³ | ≥15% and total CD4 cell count of ≥200/mm ³ | | | | | | |
| Hepatitis B | | | | | | | | | | |
| Rotavirus | | SCID ² | | | | | | | | |
| Diphtheria, tetanus, and acellular pertussis (DTaP) | | | | | | | | | | |
| <i>Haemophilus influenzae</i> type b | | | | | | | | | | |
| Pneumococcal conjugate | | | | | | | | | | |
| Inactivated poliovirus | | | | | | | | | | |
| Influenza (IIV4) | | | | | | | | | | |
| OR | | | | | | | | | | |
| Influenza (LAIV4) | | | | | | Asthma, wheezing: 2–4yrs ¹ | | | | |
| Measles, mumps, rubella | * | | | | | | | | | |
| Varicella | * | | | | | | | | | |
| Hepatitis A | | | | | | | | | | |
| Tetanus, diphtheria, and acellular pertussis (Tdap) | | | | | | | | | | |
| Human papillomavirus | * | | | | | | | | | |
| Meningococcal ACWY | | | | | | | | | | |
| Meningococcal B | | | | | | | | | | |
| Pneumococcal polysaccharide | | | | | | | | | | |
| Dengue | | | | | | | | | | |

Vaccination according to the routine schedule recommended

Recommended for persons with an additional risk factor for which the vaccine would be indicated

Vaccination is recommended, and additional doses may be necessary based on medical condition or vaccine. See Notes.

Precaution—vaccine might be indicated if benefit of protection outweighs risk of adverse reaction

Contraindicated or not recommended—vaccine should not be administered

No recommendation/not applicable

¹Vaccinate after pregnancy

1 For additional information regarding HIV laboratory parameters and use of live vaccines, see the *General Best Practice Guidelines for Immunization*, "Altered Immunocompetence," at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html and Table 4-1 (footnote J) at www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html.
 2 Severe Combined Immunodeficiency

Child and Adolescents Immunization

Revision #5

Created 12 February 2022 21:20:49 by PHILLIP KIM

Updated 4 April 2022 05:03:55 by Katarina Soewono